董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| R. Kent McGaughy, Jr. | 男 | Director | 49 | 2.25万美元 | 未持股 | 2021-03-15 |
| Neil Gibson | 男 | Lead Independent Director | 65 | 8.19万美元 | 未持股 | 2021-03-15 |
| Gwendolyn Binder | 女 | Director | 46 | 4.25万美元 | 未持股 | 2021-03-15 |
| George Matcham | 男 | Director | 68 | 2.25万美元 | 未持股 | 2021-03-15 |
| Bronson Crouch | 男 | Chief Executive Officer and Chairman | 48 | 573.37万美元 | 未持股 | 2021-03-15 |
| Nimish Shah | 男 | Director | 43 | 2.25万美元 | 未持股 | 2021-03-15 |
| Jack B. Nielsen | 男 | Director | 57 | 2.25万美元 | 未持股 | 2021-03-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sandeep Laumas | 男 | Chief Financial Officer and Chief Business Officer | 52 | 136.57万美元 | 未持股 | 2021-03-15 |
| Bronson Crouch | 男 | Chief Executive Officer and Chairman | 48 | 573.37万美元 | 未持股 | 2021-03-15 |
| Zachary Roberts | 男 | Chief Medical Officer | 43 | 219.58万美元 | 未持股 | 2021-03-15 |
| Vijay Chiruvolu | 男 | Chief Technical Officer | 59 | 未披露 | 未持股 | 2021-03-15 |
董事简历
中英对照 | 中文 | 英文- R. Kent McGaughy, Jr.
-
R. Kent McGaughy, Jr.自2004年12月起担任董事会成员。McGaughy先生自2006年以来一直是CPMG，Inc.的合伙人。在加入CPMG的前身Cardinal Investment Company，Inc.之前，他于1997年在Simmons & Company International工作。他目前在上市公司Apollo Endosurgery, Inc.和几家私营公司的董事会任职。McGaughy先生获得了学士学位。以优异成绩获得德克萨斯大学和Phi Beta Kappa成员，并获得哈佛商学院的工商管理硕士学位。
R. Kent McGaughy, Jr. has served as a member of the Board since December 2004. Mr. McGaughy has been a partner in CPMG, Inc. since 2006. Prior to joining CPMG's predecessor, Cardinal Investment Company, Inc., in 1997 he worked at Simmons & Company International. He currently serves on the boards of Apollo Endosurgery, Inc., a publicly traded company, and several private companies. Mr. McGaughy received his B.A. from The University of Texas summa cum laude and member of Phi Beta Kappa and his M.B.A. from Harvard Business School. - R. Kent McGaughy, Jr.自2004年12月起担任董事会成员。McGaughy先生自2006年以来一直是CPMG，Inc.的合伙人。在加入CPMG的前身Cardinal Investment Company，Inc.之前，他于1997年在Simmons & Company International工作。他目前在上市公司Apollo Endosurgery, Inc.和几家私营公司的董事会任职。McGaughy先生获得了学士学位。以优异成绩获得德克萨斯大学和Phi Beta Kappa成员，并获得哈佛商学院的工商管理硕士学位。
- R. Kent McGaughy, Jr. has served as a member of the Board since December 2004. Mr. McGaughy has been a partner in CPMG, Inc. since 2006. Prior to joining CPMG's predecessor, Cardinal Investment Company, Inc., in 1997 he worked at Simmons & Company International. He currently serves on the boards of Apollo Endosurgery, Inc., a publicly traded company, and several private companies. Mr. McGaughy received his B.A. from The University of Texas summa cum laude and member of Phi Beta Kappa and his M.B.A. from Harvard Business School.
- Neil Gibson
-
Neil Gibson自2020年6月起担任董事会成员，自2021年3月起担任首席独立董事。吉布森博士自2017年以来一直担任COI Pharmaceuticals，Inc.公司Adanate的总裁兼首席执行官。吉布森博士曾在生物技术和制药行业担任多个高级职位，包括2017年至2020年担任PDI Therapeutics的总裁兼首席执行官，2015年至2016年担任Bioatla，Inc.高级副总裁，2011年至2015年担任Regulus Therapeutics的首席科学官。吉布森博士自2017年以来一直担任TCR2和Causeway Therapeutics的董事会成员，此前曾于2016年至2019年担任Cytosen Therapeutics的董事会成员。吉布森博士获得了理学学士学位。the University of Strathclyde的药学博士学位和the University of Aston的博士学位。
Neil Gibson,most recently served as Senior Vice President of COI Pharmaceuticals, Inc., an accelerator company focused on the creation and development of unique drug discovery companies based on innovative and disruptive technologies, from October 2016 to December 2021. Previously, he served as President and Chief Executive Officer of Adanate from 2017 to November 2021 and President and Chief Executive Officer of PDI Therapeutics from 2017 to June 2020, both COI Pharmaceuticals, Inc. companies. Dr. Gibson has also served in leadership roles at various biotechnology companies, including Senior Vice President of BioAtla, Inc. (Nasdaq: BCAB) from 2015 to 2016; Chief Scientific Officer of Regulus Therapeutics Inc. (Nasdaq: RGLS) from 2011 to 2015; Chief Scientific Officer and Oncology Therapeutic Area Head of Pfizer Oncology from 2007 to 2011; and Chief Scientific Officer of OSI Pharmaceuticals, Inc. from 2000 to 2007. While at Pfizer, Dr. Gibson was also a member of the Pfizer Oncology Business Unit Executive team. Dr. Gibson has served on the boards of TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company, and Causeway Therapeutics, a clinical-stage biopharmaceutical company, since 2017, the board of Adanate, Inc., a biotechnology company, since 2022, and Instil Bio, Inc. (Nasdaq: TIL), a clinical-stage biopharmaceutical company, since June 2020. He previously served on the boards of Cullinan MICA, a biotechnology company, from 2020 to 2022, and CytoSen Therapeutics, Inc., a biopharmaceutical company, from 2016 to 2019. Dr. Gibson earned his B.Sc. in Pharmacy from the University of Strathclyde in Glasgow, Scotland and his Ph.D. from the University of Aston in Birmingham, England. - Neil Gibson自2020年6月起担任董事会成员，自2021年3月起担任首席独立董事。吉布森博士自2017年以来一直担任COI Pharmaceuticals，Inc.公司Adanate的总裁兼首席执行官。吉布森博士曾在生物技术和制药行业担任多个高级职位，包括2017年至2020年担任PDI Therapeutics的总裁兼首席执行官，2015年至2016年担任Bioatla，Inc.高级副总裁，2011年至2015年担任Regulus Therapeutics的首席科学官。吉布森博士自2017年以来一直担任TCR2和Causeway Therapeutics的董事会成员，此前曾于2016年至2019年担任Cytosen Therapeutics的董事会成员。吉布森博士获得了理学学士学位。the University of Strathclyde的药学博士学位和the University of Aston的博士学位。
- Neil Gibson,most recently served as Senior Vice President of COI Pharmaceuticals, Inc., an accelerator company focused on the creation and development of unique drug discovery companies based on innovative and disruptive technologies, from October 2016 to December 2021. Previously, he served as President and Chief Executive Officer of Adanate from 2017 to November 2021 and President and Chief Executive Officer of PDI Therapeutics from 2017 to June 2020, both COI Pharmaceuticals, Inc. companies. Dr. Gibson has also served in leadership roles at various biotechnology companies, including Senior Vice President of BioAtla, Inc. (Nasdaq: BCAB) from 2015 to 2016; Chief Scientific Officer of Regulus Therapeutics Inc. (Nasdaq: RGLS) from 2011 to 2015; Chief Scientific Officer and Oncology Therapeutic Area Head of Pfizer Oncology from 2007 to 2011; and Chief Scientific Officer of OSI Pharmaceuticals, Inc. from 2000 to 2007. While at Pfizer, Dr. Gibson was also a member of the Pfizer Oncology Business Unit Executive team. Dr. Gibson has served on the boards of TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company, and Causeway Therapeutics, a clinical-stage biopharmaceutical company, since 2017, the board of Adanate, Inc., a biotechnology company, since 2022, and Instil Bio, Inc. (Nasdaq: TIL), a clinical-stage biopharmaceutical company, since June 2020. He previously served on the boards of Cullinan MICA, a biotechnology company, from 2020 to 2022, and CytoSen Therapeutics, Inc., a biopharmaceutical company, from 2016 to 2019. Dr. Gibson earned his B.Sc. in Pharmacy from the University of Strathclyde in Glasgow, Scotland and his Ph.D. from the University of Aston in Birmingham, England.
- Gwendolyn Binder
-
Gwendolyn Binder自2020年7月以来一直担任我们的董事会成员。Binder博士自2019年2月起担任CabalettaBio，Inc.科技执行Vice President。Binder博士曾于2011年3月至2019年1月在Adaptimmune治疗有限公司担任多个职位，最近于2016年3月至2019年1月担任首席技术官，并于2011年3月至2016年2月担任执行Vice President，翻译科学主管。Binder博士在威尔斯学院（Wells College）获得生物化学与分子生物学学士学位，并在约翰霍普金斯大学（John Hopkins University）获得细胞与分子医学博士学位。
Gwendolyn Binder has served as a member of our board of directors since July 2020. Dr. Binder has served as Executive Vice President of Science and Technology of Cabaletta Bio, Inc. since February 2019. Dr. Binder previously served in various roles for Adaptimmune Therapeutics PLC from March 2011 to January 2019 most recently as Chief Technology Officer from March 2016 to January 2019 and Executive Vice President, Head of Translational Sciences from March 2011 to February 2016. Dr. Binder earned her B.A. from Wells College in biochemistry and molecular biology and Ph.D. in cellular and molecular medicine from the John Hopkins University. - Gwendolyn Binder自2020年7月以来一直担任我们的董事会成员。Binder博士自2019年2月起担任CabalettaBio，Inc.科技执行Vice President。Binder博士曾于2011年3月至2019年1月在Adaptimmune治疗有限公司担任多个职位，最近于2016年3月至2019年1月担任首席技术官，并于2011年3月至2016年2月担任执行Vice President，翻译科学主管。Binder博士在威尔斯学院（Wells College）获得生物化学与分子生物学学士学位，并在约翰霍普金斯大学（John Hopkins University）获得细胞与分子医学博士学位。
- Gwendolyn Binder has served as a member of our board of directors since July 2020. Dr. Binder has served as Executive Vice President of Science and Technology of Cabaletta Bio, Inc. since February 2019. Dr. Binder previously served in various roles for Adaptimmune Therapeutics PLC from March 2011 to January 2019 most recently as Chief Technology Officer from March 2016 to January 2019 and Executive Vice President, Head of Translational Sciences from March 2011 to February 2016. Dr. Binder earned her B.A. from Wells College in biochemistry and molecular biology and Ph.D. in cellular and molecular medicine from the John Hopkins University.
- George Matcham
-
George Matcham自2018年9月以来一直担任我们的董事会成员。他曾担任新基医药公司的多种职务（1988年以来），最近担任高级副总裁，Car T CMC&Technology Development（2017年8月至2018年6月）和高级副总裁，2013年5月至2017年8月，负责生物制剂的开发和制造，2015年9月起负责CAR T CMC&制造。Matcham博士获得了理学学士学位。以及Cardiff University生物化学博士学位。
George Matcham has served as a member of our board of directors since September 2018. He previously served in various roles for Celgene Corporation since 1988 most recently as Senior Vice President, CAR T CMC & Technology Development from August 2017 to June 2018 and Senior Vice President, Biologics Development and Manufacturing from May 2013 to August 2017 with responsibility for CAR T CMC & Manufacturing from September 2015. Dr. Matcham received his B.Sc. and Ph.D. in biochemistry from Cardiff University. - George Matcham自2018年9月以来一直担任我们的董事会成员。他曾担任新基医药公司的多种职务（1988年以来），最近担任高级副总裁，Car T CMC&Technology Development（2017年8月至2018年6月）和高级副总裁，2013年5月至2017年8月，负责生物制剂的开发和制造，2015年9月起负责CAR T CMC&制造。Matcham博士获得了理学学士学位。以及Cardiff University生物化学博士学位。
- George Matcham has served as a member of our board of directors since September 2018. He previously served in various roles for Celgene Corporation since 1988 most recently as Senior Vice President, CAR T CMC & Technology Development from August 2017 to June 2018 and Senior Vice President, Biologics Development and Manufacturing from May 2013 to August 2017 with responsibility for CAR T CMC & Manufacturing from September 2015. Dr. Matcham received his B.Sc. and Ph.D. in biochemistry from Cardiff University.
- Bronson Crouch
-
Bronson Crouch自2018年11月起担任我们的首席执行官兼董事会主席。除了担任我们的首席执行官兼主席外，Crouch先生自2014年1月起担任Computional Ventures Management LLC的创始合伙人。
Bronson Crouch has served as our Chief Executive Officer and Chairman of our board of directors since November 2018. In addition to serving as our Chief Executive Officer and Chairman, Mr. Crouch has served as Founding Partner of Curative Ventures Management LLC since January 2014. - Bronson Crouch自2018年11月起担任我们的首席执行官兼董事会主席。除了担任我们的首席执行官兼主席外，Crouch先生自2014年1月起担任Computional Ventures Management LLC的创始合伙人。
- Bronson Crouch has served as our Chief Executive Officer and Chairman of our board of directors since November 2018. In addition to serving as our Chief Executive Officer and Chairman, Mr. Crouch has served as Founding Partner of Curative Ventures Management LLC since January 2014.
- Nimish Shah
-
Nimish Shah，联合创立Apogee，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2022年起担任Apogee Therapeutics，LLC董事会成员。沙阿是投资公司Venrock Healthcare Capital Partners的合伙人，他主要为Venrock的公开和交叉生物技术基金工作。沙阿最初于2013年加入Venrock，自2010年以来一直投资于公共和私营医疗保健公司。Shah先生曾担任Instil Bio, Inc.（纳斯达克：TIL）董事，LianBio（纳斯达克：LIAN）、Biohaven Ltd.（纽约证券交易所：BHVN）和Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会观察员。他还是Dianthus Therapeutics，Inc.的董事会观察员。Shah先生在罗格斯药学院获得药学学士学位，在哥伦比亚大学梅尔曼公共卫生学院获得公共卫生硕士学位，在哥伦比亚商学院获得工商管理硕士学位。他是哥伦比亚商学院医疗和药品管理顾问委员会的成员。
Nimish Shah,co-founded Apogee and has served as a member of Apogee Therapeutics, Inc. Board since June 2023 and as a member of the board of managers of Apogee Therapeutics, LLC since 2022. Mr. Shah is a partner at Venrock Healthcare Capital Partners, an investment firm, where he predominately works on Venrock's public and cross-over biotech funds. Mr. Shah originally joined Venrock in 2013 and has been investing in public and private healthcare companies since 2010. Mr. Shah previously served as a director for Instil Bio, Inc. (Nasdaq: TIL) and board observer for LianBio (NASDAQ: LIAN), Biohaven Ltd. (NYSE: BHVN) and Viridian Therapeutics, Inc. (Nasdaq: VRDN). He is also a board observer for Dianthus Therapeutics, Inc. Mr. Shah received his B.S. in pharmacy from Rutgers College of Pharmacy, M.P.H. from the Mailman School of Public Health at Columbia University and M.B.A. from Columbia Business School. He is a member of the Columbia Business School Healthcare and Pharmaceutical Management Advisory Board. - Nimish Shah，联合创立Apogee，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2022年起担任Apogee Therapeutics，LLC董事会成员。沙阿是投资公司Venrock Healthcare Capital Partners的合伙人，他主要为Venrock的公开和交叉生物技术基金工作。沙阿最初于2013年加入Venrock，自2010年以来一直投资于公共和私营医疗保健公司。Shah先生曾担任Instil Bio, Inc.（纳斯达克：TIL）董事，LianBio（纳斯达克：LIAN）、Biohaven Ltd.（纽约证券交易所：BHVN）和Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会观察员。他还是Dianthus Therapeutics，Inc.的董事会观察员。Shah先生在罗格斯药学院获得药学学士学位，在哥伦比亚大学梅尔曼公共卫生学院获得公共卫生硕士学位，在哥伦比亚商学院获得工商管理硕士学位。他是哥伦比亚商学院医疗和药品管理顾问委员会的成员。
- Nimish Shah,co-founded Apogee and has served as a member of Apogee Therapeutics, Inc. Board since June 2023 and as a member of the board of managers of Apogee Therapeutics, LLC since 2022. Mr. Shah is a partner at Venrock Healthcare Capital Partners, an investment firm, where he predominately works on Venrock's public and cross-over biotech funds. Mr. Shah originally joined Venrock in 2013 and has been investing in public and private healthcare companies since 2010. Mr. Shah previously served as a director for Instil Bio, Inc. (Nasdaq: TIL) and board observer for LianBio (NASDAQ: LIAN), Biohaven Ltd. (NYSE: BHVN) and Viridian Therapeutics, Inc. (Nasdaq: VRDN). He is also a board observer for Dianthus Therapeutics, Inc. Mr. Shah received his B.S. in pharmacy from Rutgers College of Pharmacy, M.P.H. from the Mailman School of Public Health at Columbia University and M.B.A. from Columbia Business School. He is a member of the Columbia Business School Healthcare and Pharmaceutical Management Advisory Board.
- Jack B. Nielsen
-
Jack B. Nielsen，自2006年10月起担任我们的董事。Nielsen先生自2001年起就在the Novo A/S organization及其风险活动方面任职，最近被聘为合伙人。2006年至2012年，Nielsen先生被Novo Ventures US Inc.聘为合伙人。1990年至2001年，他在Novo Nordisk（2000年成为Novozymes A/S）担任多个职位。Nielsen先生目前是Akebia Therapeutics, Inc., Alios BioPharma Inc., Apollo Endosurgery Inc., BioClin Therapeutics Inc., Reata Pharmaceuticals Inc.和Tobira Therapeutics Inc.的董事。 Nielsen先生于1990年获得了Technical University of Denmark的硕士学位，2000年获得哥本哈根the Center for Technology, Economics and Management的技术管理硕士学位。
Jack B. Nielsen has served as a member our board of directors since January 2021. Since August 2017 Mr. Nielsen has served as a Managing Director at Vivo Capital LLC, a healthcare focused investment firm and was recently promoted as a Managing Partner. Prior to March 2017 Mr. Nielsen worked within the Novo Holdings A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. Mr. Nielsen is currently a member of the board of directors of Aligos Therapeutics, Inc., Reata Pharmaceuticals, Inc., Harmony Biosciences, ALX Oncology Holdings Inc. and Instil Bio, Inc., all of which are publicly traded companies, and a number of private companies. Mr. Nielsen, in the past, has served on the boards of directors of Akebia Therapeutics, Inc., Crinetics Pharmaceuticals, Inc., Merus, N.V. and Apollo Endosurgery, Inc., each of which is publicly traded. Mr. Nielsen received a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Masters in Management of Technology and Economics from the Center for Technology, Economics and Management, Technical University of Denmark. - Jack B. Nielsen，自2006年10月起担任我们的董事。Nielsen先生自2001年起就在the Novo A/S organization及其风险活动方面任职，最近被聘为合伙人。2006年至2012年，Nielsen先生被Novo Ventures US Inc.聘为合伙人。1990年至2001年，他在Novo Nordisk（2000年成为Novozymes A/S）担任多个职位。Nielsen先生目前是Akebia Therapeutics, Inc., Alios BioPharma Inc., Apollo Endosurgery Inc., BioClin Therapeutics Inc., Reata Pharmaceuticals Inc.和Tobira Therapeutics Inc.的董事。 Nielsen先生于1990年获得了Technical University of Denmark的硕士学位，2000年获得哥本哈根the Center for Technology, Economics and Management的技术管理硕士学位。
- Jack B. Nielsen has served as a member our board of directors since January 2021. Since August 2017 Mr. Nielsen has served as a Managing Director at Vivo Capital LLC, a healthcare focused investment firm and was recently promoted as a Managing Partner. Prior to March 2017 Mr. Nielsen worked within the Novo Holdings A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. Mr. Nielsen is currently a member of the board of directors of Aligos Therapeutics, Inc., Reata Pharmaceuticals, Inc., Harmony Biosciences, ALX Oncology Holdings Inc. and Instil Bio, Inc., all of which are publicly traded companies, and a number of private companies. Mr. Nielsen, in the past, has served on the boards of directors of Akebia Therapeutics, Inc., Crinetics Pharmaceuticals, Inc., Merus, N.V. and Apollo Endosurgery, Inc., each of which is publicly traded. Mr. Nielsen received a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Masters in Management of Technology and Economics from the Center for Technology, Economics and Management, Technical University of Denmark.
高管简历
中英对照 | 中文 | 英文- Sandeep Laumas
Sandeep Laumas自2021年2月起担任我们的首席财务官，自2020年6月起担任我们的首席商务官。他目前自2020年5月起担任9MetersBiopharma，Inc.董事会成员，此前曾于2014年1月至2020年4月担任执行主席，包括2019年2月至2020年4月担任首席执行官。Laumas博士自2017年9月起担任BioxcelTherapeutics，Inc.董事会成员兼审计委员会主席。Laumas博士在康奈尔大学（Cornell University）获得化学学士学位，在奥尔巴尼医学院（Albany Medical College）获得医学博士学位，他在耶鲁大学医学院（Yale University School of Medicine）完成医学实习。
Sandeep Laumas has served as a director of Bioxcel Therapeutics, Inc. since September 2017. Dr. Laumas has served as the Chief Financial Officer and Chief Biness Officer of Instil Bio, Inc. since February 2021 and June 2020, respectively. He began his career at Goldman Sachs & Co. in 1996 in the healthcare investment banking division before transitioning to the healthcare equity research division. He was an analyst at Balyasny Asset Management from 2001 03 and then a Managing Director of North Sound Capital from 2003 07, where he was responsible for the global healthcare investment portfolio. He founded and managed Bearing Circle Capital, an investment partnership, since 2008. Dr. Laumas has served as a member of the board of directors of Bioxcel Therapeutics Inc. since 2017 and a board member of Unicycive Therapeutics Inc. since 2018. He previoly served as a board member of 9 Meters Biopharma, Inc. from 2020 21, its Executive Chairman from 2014 20, including its Chief Executive Officer from 2019 20. Dr. Laumas received his A.B. from Cornell University in 1990, his M.D. from Albany Medical College in 1995, with a research year at the Dana Farber Cancer Institute and completed his medical internship at the Yale University School of Medicine in 1996.- Sandeep Laumas自2021年2月起担任我们的首席财务官，自2020年6月起担任我们的首席商务官。他目前自2020年5月起担任9MetersBiopharma，Inc.董事会成员，此前曾于2014年1月至2020年4月担任执行主席，包括2019年2月至2020年4月担任首席执行官。Laumas博士自2017年9月起担任BioxcelTherapeutics，Inc.董事会成员兼审计委员会主席。Laumas博士在康奈尔大学（Cornell University）获得化学学士学位，在奥尔巴尼医学院（Albany Medical College）获得医学博士学位，他在耶鲁大学医学院（Yale University School of Medicine）完成医学实习。
- Sandeep Laumas has served as a director of Bioxcel Therapeutics, Inc. since September 2017. Dr. Laumas has served as the Chief Financial Officer and Chief Biness Officer of Instil Bio, Inc. since February 2021 and June 2020, respectively. He began his career at Goldman Sachs & Co. in 1996 in the healthcare investment banking division before transitioning to the healthcare equity research division. He was an analyst at Balyasny Asset Management from 2001 03 and then a Managing Director of North Sound Capital from 2003 07, where he was responsible for the global healthcare investment portfolio. He founded and managed Bearing Circle Capital, an investment partnership, since 2008. Dr. Laumas has served as a member of the board of directors of Bioxcel Therapeutics Inc. since 2017 and a board member of Unicycive Therapeutics Inc. since 2018. He previoly served as a board member of 9 Meters Biopharma, Inc. from 2020 21, its Executive Chairman from 2014 20, including its Chief Executive Officer from 2019 20. Dr. Laumas received his A.B. from Cornell University in 1990, his M.D. from Albany Medical College in 1995, with a research year at the Dana Farber Cancer Institute and completed his medical internship at the Yale University School of Medicine in 1996.
- Bronson Crouch
Bronson Crouch自2018年11月起担任我们的首席执行官兼董事会主席。除了担任我们的首席执行官兼主席外，Crouch先生自2014年1月起担任Computional Ventures Management LLC的创始合伙人。
Bronson Crouch has served as our Chief Executive Officer and Chairman of our board of directors since November 2018. In addition to serving as our Chief Executive Officer and Chairman, Mr. Crouch has served as Founding Partner of Curative Ventures Management LLC since January 2014.- Bronson Crouch自2018年11月起担任我们的首席执行官兼董事会主席。除了担任我们的首席执行官兼主席外，Crouch先生自2014年1月起担任Computional Ventures Management LLC的创始合伙人。
- Bronson Crouch has served as our Chief Executive Officer and Chairman of our board of directors since November 2018. In addition to serving as our Chief Executive Officer and Chairman, Mr. Crouch has served as Founding Partner of Curative Ventures Management LLC since January 2014.
- Zachary Roberts
Zachary Roberts自2020年3月起担任我们的首席医疗官。加入我们之前，他曾担任KitePharma，Inc./吉利德科学公司（Gilead Sciences）的多种职务，最近担任Vice President，负责临床开发（2018年2月至2019年5月）。在加入Kite之前，Roberts博士于2015年1月至2015年7月担任Amgen Oncology的临床研究医学总监。Roberts博士在麻省总医院（Massachusetts General Hospital）和Dana Farber癌症研究所（Dana Farber Cancer Institute）完成了内科和血液学/肿瘤学的培训。他在University of Maryland，College Park获得微生物学和免疫学学士学位，在University of Maryland，Baltimore获得免疫学博士学位和硕士学位。
Zachary Roberts has served as our Chief Medical Officer since March 2020. Prior to joining us, he served in various roles for Kite Pharma, Inc./Gilead Sciences, most recently as Vice President, Clinical Development from February 2018 to May 2019. Prior to joining Kite, Dr. Roberts served as Clinical Research Medical Director for Amgen Oncology from January 2015 to July 2015. Dr. Roberts completed his training in internal medicine and hematology/oncology at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his B.S. in microbiology and immunology from the University of Maryland, College Park and both his Ph.D. in immunology and his M.D from the University of Maryland, Baltimore.- Zachary Roberts自2020年3月起担任我们的首席医疗官。加入我们之前，他曾担任KitePharma，Inc./吉利德科学公司（Gilead Sciences）的多种职务，最近担任Vice President，负责临床开发（2018年2月至2019年5月）。在加入Kite之前，Roberts博士于2015年1月至2015年7月担任Amgen Oncology的临床研究医学总监。Roberts博士在麻省总医院（Massachusetts General Hospital）和Dana Farber癌症研究所（Dana Farber Cancer Institute）完成了内科和血液学/肿瘤学的培训。他在University of Maryland，College Park获得微生物学和免疫学学士学位，在University of Maryland，Baltimore获得免疫学博士学位和硕士学位。
- Zachary Roberts has served as our Chief Medical Officer since March 2020. Prior to joining us, he served in various roles for Kite Pharma, Inc./Gilead Sciences, most recently as Vice President, Clinical Development from February 2018 to May 2019. Prior to joining Kite, Dr. Roberts served as Clinical Research Medical Director for Amgen Oncology from January 2015 to July 2015. Dr. Roberts completed his training in internal medicine and hematology/oncology at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his B.S. in microbiology and immunology from the University of Maryland, College Park and both his Ph.D. in immunology and his M.D from the University of Maryland, Baltimore.
- Vijay Chiruvolu
Vijay Chiruvolu自2020年7月起担任我们的首席技术官。在加入我们之前，他曾于2014年9月至2020年7月担任KitePharma，Inc./Gilead Sciences的高级副总裁，全球过程开发-细胞疗法。任职Kite公司期间，Chiruvolu博士负责CMC/工艺开发，导致两种细胞治疗产品Yescarta和Tecartus的监管批准。在加入Kite之前，1996年至2014年，Chiruvolu博士在SCIOS，Avigen，Hoffmann-La Roche，强生公司和Amgen担任了18年的过程开发，制造，供应链和质量方面的职责不断增加。Chiruvolu博士拥有University of Nebraska工程生化博士学位和Pennsylvania State University工商管理硕士学位。
Vijay Chiruvolu has served as our Chief Technical Officer since July 2020. Prior to joining us, he served as the Senior Vice President, Global Process Development-Cell Therapy of Kite Pharma, Inc./Gilead Sciences, from September 2014 to July 2020. During his time at Kite, Dr. Chiruvolu was responsible for the CMC/process development leading to the regulatory approval of two cell therapy products, Yescarta and Tecartus. Prior to joining Kite, from 1996 to 2014 Dr. Chiruvolu spent 18 years in positions of increasing responsibility in Process Development, Manufacturing, Supply Chain and Quality at Scios, Avigen, Hoffmann-La Roche, Johnson & Johnson and Amgen. Dr. Chiruvolu holds a Ph.D. in Engineering Biochemical from University of Nebraska and M.B.A. from Pennsylvania State University.- Vijay Chiruvolu自2020年7月起担任我们的首席技术官。在加入我们之前，他曾于2014年9月至2020年7月担任KitePharma，Inc./Gilead Sciences的高级副总裁，全球过程开发-细胞疗法。任职Kite公司期间，Chiruvolu博士负责CMC/工艺开发，导致两种细胞治疗产品Yescarta和Tecartus的监管批准。在加入Kite之前，1996年至2014年，Chiruvolu博士在SCIOS，Avigen，Hoffmann-La Roche，强生公司和Amgen担任了18年的过程开发，制造，供应链和质量方面的职责不断增加。Chiruvolu博士拥有University of Nebraska工程生化博士学位和Pennsylvania State University工商管理硕士学位。
- Vijay Chiruvolu has served as our Chief Technical Officer since July 2020. Prior to joining us, he served as the Senior Vice President, Global Process Development-Cell Therapy of Kite Pharma, Inc./Gilead Sciences, from September 2014 to July 2020. During his time at Kite, Dr. Chiruvolu was responsible for the CMC/process development leading to the regulatory approval of two cell therapy products, Yescarta and Tecartus. Prior to joining Kite, from 1996 to 2014 Dr. Chiruvolu spent 18 years in positions of increasing responsibility in Process Development, Manufacturing, Supply Chain and Quality at Scios, Avigen, Hoffmann-La Roche, Johnson & Johnson and Amgen. Dr. Chiruvolu holds a Ph.D. in Engineering Biochemical from University of Nebraska and M.B.A. from Pennsylvania State University.